enGene Holdings Inc. (ENGN)

Market Cap	382.33M
Revenue (ttm)	n/a
Net Income (ttm)	-123.44M
Shares Out	50.98M
EPS (ttm)	-4.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,923
Open	7.50
Previous Close	7.52
Day's Range	7.30 - 7.80
52-Week Range	4.42 - 18.40
Beta	-0.76
Analysts	Strong Buy
Price Target	31.43 (+319.07%)
Earnings Date	Sep 10, 2024

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Forecast

According to 7 analysts, the average rating for ENGN stock is "Strong Buy." The 12-month stock price forecast is $31.43, which is an increase of 319.07% from the latest price.

Price Target

$31.43

(319.07% upside)

Analyst Consensus: Strong Buy